key: cord-1021161-9rxdzb0c
authors: Tian, Xiaodong; Liu, Ling; Jiang, Wenguo; Zhang, He; Liu, Wenjun; Li, Jing
title: Potent and Persistent Antibody Response in COVID-19 Recovered Patients
date: 2021-05-28
journal: Front Immunol
DOI: 10.3389/fimmu.2021.659041
sha: 39fd2b82e5f7b2b467e7dc608b7ecbf232434cbd
doc_id: 1021161
cord_uid: 9rxdzb0c

SARS-CoV-2 has caused a global pandemic with millions infected and numerous fatalities. Virus-specific antibodies can be detected in infected patients approximately two weeks after symptom onset. In this study, we set up ELISA technology coating with purified SARS-CoV-2 S and N proteins to study the antibody response of 484 serum samples. We established a surrogate viral inhibition assay using SARS-CoV-2 S protein pseudovirus system to determine the neutralization potency of collected serum samples. Here, we report robust antibody responses to SARS-CoV-2 in 484 recovered patients varying from 154 to 193 days, with 92% of recovered patients displaying a positive virus-specific spike glycoprotein IgG (s-IgG) response, while the ratio of positive spike glycoprotein IgM (s-IgM) reached 63%. Furthermore, moderate to potent neutralization activities were also observed in 62% of patients, correlating significantly with s-IgG response. This study strongly supports the long-term presence of antibodies in recovered patients against SARS-CoV-2, although all serum samples were collected from individuals with mild or moderate symptoms.

addition, a serological survey of 175 mild cases demonstrated that neutralizing antibodies were produced 10-15 days after the onset of SARS-CoV-2 infection and that middle-aged and elderly patients produced much higher neutralizing antibody titers than young patients. However, 30% of patients exhibited very low antibody titers; among these, the antibody titers of ten convalescent patients failed to reach the detection limit, highlighting an important limitation to mapping the epidemiology of SARS-CoV-2 infection by antibody detection (3, 4) . As the SARS-CoV-2 pandemic emerged, quite a few asymptomatic cases of SARS-CoV-2 infection were observed, rendering it critical to investigate the immunological characteristics of such asymptomatic cases (5) . Previous study shown that IgG antibody levels of the asymptomatic group were significantly lower than those of the symptomatic group in both the acute infection stage and the convalescent stage. The antibody levels in about 90% of the cases had decreased by 70% or more two months after discharge, suggesting that serological testing should be carried out as soon as possible. Furthermore, decreased neutralizing antibody levels were also observed in about 80% and 69% of asymptomatic and symptomatic cases, respectively, with an average reduction of about 8% and 11%, respectively (6) . However, the recently published research demonstrated that SARS-CoV-2 infected hospitalized patients displayed durable and stable antibodies response (7) (8) (9) . SARS-CoV-2 infected asymptomatic patients shown the similar trend, although the neutralizing antibody titers were lower compared with confirmed cases and symptomatic individuals (10) .

Due to their specificity and high affinity, neutralizing antibodies play a role in protecting host cells from invasion by neutralizing or inhibiting the biological activity of pathogens, suggesting that neutralizing antibodies may be used as both prophylactic and therapeutic drugs in high-exposure situations (11, 12) . At present, multiple monoclonal antibodies-screened and identified by high-throughput single-cell sequencing and fluorescence-activated cell sorting-have proven to be effective against the SARS-CoV-2 spike protein-receptor-binding domain (RBD), revealing that anti-SARS-CoV-2 spike protein-RBD monoclonal antibodies may serve as potential therapeutic candidates for SARS-CoV-2 infection (13) (14) (15) (16) . Moreover, a recently published study found that numerous antibodies in patients also played a neutralizing role without binding to the RBD, indicating that the use of highly active antiretroviral therapy-commonly known as "cocktail therapy"-may have greater therapeutic potential in combination with multiple antibodies against different antigenic epitopes (17) (18) (19) .

Monitoring the immune response in infected and convalescent patients is critical to analyzing the pathogenic mechanism of SARS-CoV-2 and guiding clinical diagnosis and treatment (20, 21) . In this study, hundreds of serum samples were collected from convalescent patients who were recovered from SARS-CoV-2 infection over a five to six-month after. Serum titers and neutralizing activities were investigated to understand the immune response of patients recovering from SARS-CoV-2 infection. A total of 484 patients recovered with COVID-19 were enrolled in this study. The characteristics of these patients are summarized in Supplemental Table 1 . All of these cases were in the hospital and correctional facility of Shandong province recovered from 154 to 193 days after diagnosis of illness. To study the antibody response to SARS-CoV-2, the IgG and IgM responses against S glycoprotein and N protein were measured by enzyme-linked immunosorbent assay (ELISA). Initially, the OD 450 at a 1:400 serum dilution was measured for 484 samples. We used the 30 healthy human serum collected before the outbreak of COVID-19 serves as negative control. The characteristics of negative controls are summarized in Supplemental Table 2 To further differentiate the antibody response against the SARS-CoV-2 virus, in addition to the results measured at 1:400 titer, ELISA was also performed in discrete ether titers of 1:800, 1:1600, and 1:3200. The 1:400 titer was categorized as low, 1:800 as moderate, 1:1600 as high, and 1:3200 as very high titers. Of the 451 IgG positive samples against S protein, 24 (5.3%) had a titer of 1:400, 43 (9.5%) of 1:800, 82 (18.2%) of 1:1600, and 302 (67%) of 1:3200 ( Figure 1A) . Thus, the majority of positive individuals had high to very high titers of anti-spike antibodies.

Determining the neutralizing effects of SARS-CoV-2 spike antibodies is critical to understand the possible protective effects of the immune response. Therefore, we measured SARS-CoV-2 neutralization potency using a surrogate viral inhibition assay that utilized lentivirus-based virus particles, pseudo-typed with the S protein of SASR-CoV-2 and 293T cells stably expressing hACE-2 receptor. All 484 individuals generated detectable neutralizing antibody responses. Of the 484 samples, 38% (NT50 value < 320) had low, 35% (NT50 value 320-640) had medium, 17% (NT50 value 1280) had high, and 9.5% (NT50 value 2560-5120) had potent neutralizing titers ( Figure 1E ). When considering candidates for plasma therapy, titers of 1:320 or higher were initially deemed eligible (22) ; 62% of serum samples displayed moderate to potent neutralization activities, indicating detectable antibody responses up to 193 days during the follow-up period.

To investigate whether serology testing correlated with sera neutralization activities, the Spearman's correlation was calculated between serum antibodies against SARS-CoV-2 S/N proteins and neutralization activity ( Figure 2 ). All sera antibodies displayed positive correlation with neutralization antibody. The highest Spearman's correlation of 0.597 was observed between S-IgG and neutralization antibody (p < 0.001). The significant positive correlations between S/N IgG and S/N IgM were also noted. The correlations between S-IgG and N-IgG were highest with Spearman's correlation coefficients of up to 0.593 (p < 0.001).

To compare the antibody response of mild and moderate COVID-19 patients, all 484 patients were separated into mild and moderate group according to the criteria of mild and moderate COVID-19, the mild patients usually presented mild non-to-mild clinical symptoms; the moderate COVID-19 patients had fever and respiratory symptoms. 340 patients were included in mild group and 144 patients were included in moderate group. We compared the proportion of recovered patients with positive virus-specific s-IgG/s-IgM/N-IgG/N-IgM between the two groups, no big difference was displayed. The similar proportion of neutralization antibody response were also displayed between these two groups, indicating even mildmoderate COVID-19 patients induce substantial antibody response. To assess whether the antibody response can predict the clinical mild to moderate symptoms, the Spearman's correlation analyses were also performed to compare serum antibodies against SARS-CoV-2 S/N proteins and neutralization activity in these two groups ( Figure 3) . Unfortunately, no significant difference was detected between two groups.

It remains a mystery whether SARS-CoV-2 infection in humans protects from reinfection and-if so-for how long; it is also unknown how long vaccine-induced antibodies might last (23) (24) (25) (26) (27) . The results of our study indicated that individuals who have recovered from mild-to-moderate symptoms generate robust antibody responses to the S protein, which is highly correlated with neutralization of the SARS-CoV-2 virus. Furthermore, we identified high antibody titers-especially S-IgG, which can be detected up to five to six months. Interestingly, we did not observe a decrease beyond the sixmonth time point, indicating a long-term presence of antibodies against SARS-CoV-2. There are several limitations in our study. Given that all serum samples were collected from individuals with moderate or mild symptoms, it is difficult to determine the 

All the experiments were carried out according to the procedures approved by the Institute of Microbiology, Chinese Academy of Sciences and complied with all relevant ethical regulations regarding animal research.

The human embryonic 293T cell line and human cells adapted in suspension (293-F cells) were stored in our laboratory. 

The human samples were obtained according to procedures approved by the Chinese Academy of Sciences, and complied with all relevant ethical regulations regarding human research. The blood was taken from the patient convalescing from COVID-19 after they had signed the informed consent form. A total of 484 serum samples were collected from prior SARS-CoV-2 nucleic acid-positive and recovered patients in hospital and correctional facility of Shandong province, China.

To produce pseudovirions, pLenti-GFP, psPAX2, and plasmids encoding SARS-CoV-2 S were co-transfected into 293F cells using polyetherimide (PEI) (Cat#40816ES03, Shanghai YEASEN Biotechnology). The cells were maintained by adding fresh medium every 48 hours. The supernatants were harvested at 5 days post transfection, passed through 0.45 mm filters and centrifuged at 2000 × g for 10 minutes to remove cell debris. The supernatant containing pseudovirions were stored at -80°C for further use. For titration of the pseudovirus, 293T/hACE2 cells were pre-plated in a 96-well plate, then the pseudovirus was diluted 5 times and each dilution contain 4 parallel control. The last column serves as the cell control without the addition of pseudovirus. After 40h incubation, 100ml of luciferase reporter substrate (Cat# RG051M, Sino Biological) was added to detect luminescence using a microplate luminometer (GloMax 96, Promega). The 50% tissue culture infection dose (TCID 50 ) was calculated using Reed-Muench method.

FIGURE 2 | Correlation between serum antibody against SARS-CoV-2 S/N proteins and neutralization activity or serum antibodies. The correlation between serum IgG and IgM antibodies against S/N proteins and neutralization activity or serum antibodies were analyzed using spearman analysis. 484 serum samples at 1: 400 dilution from recovered patients were detected using ELISA assay. The neutralization antibody titer was also measure at 1:320 dilution. Spearman correlation coefficients are depicted in plots. 

Human 293T cells stably expressing hACE2 were inoculated in a 96-well plate 24 hours before the experiment. The serum samples were heat-inactivated at 56°C for 30 minutes prior to use. Beginning with a 1:10 dilution, twofold serial dilutions of each sample were prepared in a 96-well plate. Equal volumes of SARS-CoV-2 pseudovirus particles were mixed with each diluted serum sample and incubated at 37°C for 1 hour. The virus-serum mixture was then added to the 293T/hACE2 cells. After incubation for 6 hours, the mixture was removed and changed to fresh medium. Forty hours later, firefly luciferase activity in the cells was detected by chemiluminescence and the luciferase activity was quantified to measure the transduction efficiency. To calculate neutralization efficiency, the same dose of pseudovirus (without antibody) serves as positive control. The positive value was determined as ten-fold relative luminescence unit (RLU) values higher than the cell only background. The half-maximal neutralization titer (NT50) value was calculated by the luciferase activity.

Data analysis was performed using GraphPad and SPSS. The data were annotated, the correlation between different antibodies was analyzed using Spearman's rank test, and the significance of the correlation coefficient was verified.

The original contributions presented in the study are included in the article/Supplementary Material. Further inquiries can be directed to the corresponding authors.

The studies involving human participants were reviewed and approved by the Institute of Microbiology, Chinese Academy of Sciences. The patients/participants provided their written informed consent to participate in this study.

JL conceived and designed the experiments. XT performed the ELISA tests, neutralization assay, and statistics analyses. LL and HZ performed other experimental data analyses. WJ performed the serum collection. JL and XT wrote the manuscript and completed its revision. WL suggested many of the experiments in this study. All authors contributed to the article and approved the submitted version. 

Kinetics of Viral Load and Antibody Response in Relation to COVID-19 Severity

Antibody Responses to SARS-CoV-2 in Patients With COVID-19

Neutralizing Antibody Response in Mild COVID-19

Neutralizing Antibody Responses to SARS-CoV-2 in a COVID-19 Recovered Patient Cohort and Their Implications. medRxiv

Asymptomatic Cases in a Family Cluster With SARS-CoV-2 Infection

Clinical and Immunological Assessment of Asymptomatic SARS-CoV-2 Infections

Humoral Immune Response to SARS-CoV-2 in Iceland

Waning of SARS-CoV-2 RBD Antibodies in Longitudinal Convalescent Plasma Samples Within 4 Months After Symptom Onset

Functional SARS-CoV-2-specific Immune Memory Persists After Mild COVID-19

Seroprevalence and Humoral Immune Durability of anti-SARS-CoV-2 Antibodies in Wuhan, China: A Longitudinal, Population-Level, Cross-Sectional Study

The Potential Danger of Suboptimal Antibody Responses in COVID-19

Neutralizing Antibodies Against SARS-CoV-2 and Other Human Coronaviruses

Potent Neutralizing Antibodies Against SARS-CoV-2 Identified by High-Throughput Single-Cell Sequencing of Convalescent Patients' B Cells

Human Neutralizing Antibodies Elicited by SARS-CoV-2 Infection

A Human Neutralizing Antibody Targets the Receptor-Binding Site of SARS-Cov-2

A Noncompeting Pair of Human Neutralizing Antibodies Block COVID-19 Virus Binding to its Receptor ACE2

A Neutralizing Human Antibody Binds to the N-terminal Domain of the Spike Protein of SARS-Cov-2

Identification of Human Single-Domain Antibodies Against SARS-Cov-2

Structural Definition of a Neutralization Epitope on the N-terminal Domain of MERS-CoV Spike Glycoprotein

Detection of SARS-CoV-2-Specific Humoral and Cellular Immunity in COVID-19 Convalescent Individuals

Phenotype and Kinetics of SARS-Cov-2-Specific T Cells

Factors Associated With Good Patient Outcomes Following Convalescent Plasma in COVID-19: A Prospective Phase Ii Clinical Trial

Longitudinal Observation and Decline of Neutralizing Antibody Responses in the Three Months Following SARS-CoV-2 Infection in Humans

Persistence of Serum and Saliva Antibody Responses to SARS-CoV-2 Spike Antigens in COVID-19 Patients

Robust Neutralizing Antibodies to SARS-CoV-2 Infection Persist for Months

Evolution of Antibody Immunity to SARS-Cov-2. bioRxiv (2020)

Immunological Memory to SARS-CoV-2 Assessed for Greater Than Six Months After Infection. bioRxiv (2020)

Characterization of Spike Glycoprotein of SARS-CoV-2 on Virus Entry and its Immune Cross-Reactivity With SARS-Cov

A Statistically Defined Endpoint Titer Determination Method for Immunoassays

SARS-Cov-2-Specific ELISA Development

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fimmu.2021.659041/ full#supplementary-material